Carbohydrate Compounds Targeting Siglec-8 for Asthma Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective prophylactic and therapeutic treatments for asthma and other allergic diseases associated with Siglec-8 expressing cells, such as eosinophils, basophils, and mast cells, as current treatments are inadequate in managing these conditions.
Innovation Solution
Development of novel carbohydrate-based chemical compounds that bind to Siglec-8, inducing apoptosis in these cells and reducing their activity or viability, thereby alleviating symptoms of asthma and allergic diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for asthma and allergic diseases, then treatment is provided, but the treatment is inadequate in managing these conditions
Solution Approach 1:
The patent changes the molecular parameter by introducing novel carbohydrate-based compounds with specific structures (Formula I and Formula II) that bind to Siglec-8 with high affinity. This structural parameter change enables selective targeting of eosinophils, basophils, and mast cells, improving treatment effectiveness for asthma and allergic diseases where current therapies are inadequate.
2Object-affected harmful factors
If Siglec-8 expressing cells are targeted for depletion, then symptoms are alleviated, but the mechanism requires novel compound development
Solution Approach 1:
The patent uses carbohydrate-based compounds as intermediary molecules that mediate between the therapeutic goal (symptom alleviation) and the target cells (Siglec-8 expressing cells). These compounds act as soluble ligands that bind to Siglec-8, inducing apoptosis of eosinophils, basophils, and mast cells without requiring direct genetic modification or complex delivery systems, thus balancing efficacy with manufacturability.
3Quantity of substance
If novel carbohydrate-based compounds are administered, then the number and activation level of Siglec-8 expressing cells decrease, but specific binding affinity is required
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups at precise positions in the carbohydrate structure. Formula I includes specific substituents (R1-R6) at defined positions on the sugar ring, while Formula II specifies particular hydroxyl group configurations. These localized structural features enable high-affinity binding to Siglec-8's binding pocket, ensuring selective depletion of target cells while maintaining specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively decrease the number and activation level of Siglec-8 expressing cells, leading to reduced symptoms and improved management of asthma and allergic diseases.
Implementation Method 1
Siglec-8 binding reduces the activity and/or viability of these cells. When bound (e.g. by specific antibodies), Siglec-8 signals eosinophils to rapidly undergo apoptosis, or programmed cell death.
Data Source
AI summary
The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well as other animals, through the administration of one or more novel, carbohydrate-based compounds.